Literature DB >> 16175177

HSP90 and the chaperoning of cancer.

Luke Whitesell1, Susan L Lindquist.   

Abstract

Standing watch over the proteome, molecular chaperones are an ancient and evolutionarily conserved class of proteins that guide the normal folding, intracellular disposition and proteolytic turnover of many of the key regulators of cell growth, differentiation and survival. This essential guardian function is subverted during oncogenesis to allow malignant transformation and to facilitate rapid somatic evolution. Pharmacologically 'bribing' the essential guard duty of the chaperone HSP90 (heat-shock protein of 90 kDa) seems to offer a unique anticancer strategy of considerable promise.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16175177     DOI: 10.1038/nrc1716

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  924 in total

1.  A chemical cross-linking method for the analysis of binding partners of heat shock protein-90 in intact cells.

Authors:  Shaoming Song; Sutapa Kole; Michel Bernier
Journal:  Biotechniques       Date:  2012-04       Impact factor: 1.993

2.  Inhibition of heat-shock protein 90 reduces Ebola virus replication.

Authors:  Darci R Smith; Sarah McCarthy; Andrew Chrovian; Gene Olinger; Andrea Stossel; Thomas W Geisbert; Lisa E Hensley; John H Connor
Journal:  Antiviral Res       Date:  2010-05-07       Impact factor: 5.970

3.  Combined in silico and experimental approach for drug design: the binding mode of peptidic and non-peptidic inhibitors to hsp90 N-terminal domain.

Authors:  Simona Tomaselli; Massimiliano Meli; Janet Plescia; Lucia Zetta; Dario C Altieri; Giorgio Colombo; Laura Ragona
Journal:  Chem Biol Drug Des       Date:  2010-11       Impact factor: 2.817

4.  SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis.

Authors:  D Li; N D Marchenko; U M Moll
Journal:  Cell Death Differ       Date:  2011-06-03       Impact factor: 15.828

5.  HSP70 inhibition by the small-molecule 2-phenylethynesulfonamide impairs protein clearance pathways in tumor cells.

Authors:  J I-Ju Leu; Julia Pimkina; Pooja Pandey; Maureen E Murphy; Donna L George
Journal:  Mol Cancer Res       Date:  2011-06-02       Impact factor: 5.852

6.  C1206, a novel curcumin derivative, potently inhibits Hsp90 and human chronic myeloid leukemia cells in vitro.

Authors:  Ying-Juan Fan; Yi-Xiang Zhou; Lian-Ru Zhang; Qiao-Fa Lin; Ping-Zhang Gao; Fang Cai; Li-Ping Zhu; Bi Liu; Jian-Hua Xu
Journal:  Acta Pharmacol Sin       Date:  2017-12-07       Impact factor: 6.150

Review 7.  New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential.

Authors:  Yanyan Li; Tao Zhang; Steven J Schwartz; Duxin Sun
Journal:  Drug Resist Updat       Date:  2009 Feb-Apr       Impact factor: 18.500

Review 8.  The Multifaceted Role of HSF1 in Tumorigenesis.

Authors:  Milad J Alasady; Marc L Mendillo
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

9.  Dissection of the ATP-induced conformational cycle of the molecular chaperone Hsp90.

Authors:  Martin Hessling; Klaus Richter; Johannes Buchner
Journal:  Nat Struct Mol Biol       Date:  2009-02-22       Impact factor: 15.369

10.  The levels of retinoic acid-inducible gene I are regulated by heat shock protein 90-alpha.

Authors:  Tomoh Matsumiya; Tadaatsu Imaizumi; Hidemi Yoshida; Kei Satoh; Matthew K Topham; Diana M Stafforini
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.